Loading stock data…
$0.99-0.02 (-2.43%)
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States.
Cardiff Oncology, Inc. in the Healthcare sector is trading at $0.98 with a market capitalization of $102M. Wall Street consensus targets $5.81 (7 analysts), implying a +493.1% move over the next 12 months. The stock is currently near its 52-week low of $0.76, remaining 37.2% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 20 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $104,000↑ | $41,000↓ | $243,000↑ | $120,000↓ | $121,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$9.62M↑ | -$12.85M↓ | -$7.83M↑ | -$11.97M↑ | -$14.78M |
| Net Income | -$9.23M↑ | -$12.35M↓ | -$7.22M↑ | -$11.26M↑ | -$13.94M |
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treatin...